131 related articles for article (PubMed ID: 19633683)
1. The pyridinylfuranopyrimidine inhibitor, PI-103, chemosensitizes glioblastoma cells for apoptosis by inhibiting DNA repair.
Westhoff MA; Kandenwein JA; Karl S; Vellanki SH; Braun V; Eramo A; Antoniadis G; Debatin KM; Fulda S
Oncogene; 2009 Oct; 28(40):3586-96. PubMed ID: 19633683
[TBL] [Abstract][Full Text] [Related]
2. A Potential Role for the Inhibition of PI3K Signaling in Glioblastoma Therapy.
Ströbele S; Schneider M; Schneele L; Siegelin MD; Nonnenmacher L; Zhou S; Karpel-Massler G; Westhoff MA; Halatsch ME; Debatin KM
PLoS One; 2015; 10(6):e0131670. PubMed ID: 26121251
[TBL] [Abstract][Full Text] [Related]
3. Opposite effects of the triple target (DNA-PK/PI3K/mTOR) inhibitor PI-103 on the radiation sensitivity of glioblastoma cell lines proficient and deficient in DNA-PKcs.
Djuzenova CS; Fischer T; Katzer A; Sisario D; Korsa T; Steussloff G; Sukhorukov VL; Flentje M
BMC Cancer; 2021 Nov; 21(1):1201. PubMed ID: 34763650
[TBL] [Abstract][Full Text] [Related]
4. PI3K Inhibitor Combined With Chemotherapy Can Enhance the Apoptosis of Neuroblastoma Cells In Vitro and In Vivo.
Geng X; Xie L; Xing H
Technol Cancer Res Treat; 2016 Oct; 15(5):716-22. PubMed ID: 26224681
[TBL] [Abstract][Full Text] [Related]
5. Synergistic effects of targeted PI3K signaling inhibition and chemotherapy in liposarcoma.
Guo S; Lopez-Marquez H; Fan KC; Choy E; Cote G; Harmon D; Nielsen GP; Yang C; Zhang C; Mankin H; Hornicek FJ; Borger DR; Duan Z
PLoS One; 2014; 9(4):e93996. PubMed ID: 24695632
[TBL] [Abstract][Full Text] [Related]
6. PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML.
Park S; Chapuis N; Bardet V; Tamburini J; Gallay N; Willems L; Knight ZA; Shokat KM; Azar N; Viguié F; Ifrah N; Dreyfus F; Mayeux P; Lacombe C; Bouscary D
Leukemia; 2008 Sep; 22(9):1698-706. PubMed ID: 18548104
[TBL] [Abstract][Full Text] [Related]
7. Identification of a novel synthetic lethality of combined inhibition of hedgehog and PI3K signaling in rhabdomyosarcoma.
Graab U; Hahn H; Fulda S
Oncotarget; 2015 Apr; 6(11):8722-35. PubMed ID: 25749378
[TBL] [Abstract][Full Text] [Related]
8. The dual PI3K/mTOR inhibitor PI-103 promotes immunosuppression, in vivo tumor growth and increases survival of sorafenib-treated melanoma cells.
López-Fauqued M; Gil R; Grueso J; Hernandez-Losa J; Pujol A; Moliné T; Recio JA
Int J Cancer; 2010 Apr; 126(7):1549-61. PubMed ID: 19810100
[TBL] [Abstract][Full Text] [Related]
9. Dual PI3K- and mTOR-inhibitor PI-103 can either enhance or reduce the radiosensitizing effect of the Hsp90 inhibitor NVP-AUY922 in tumor cells: The role of drug-irradiation schedule.
Djuzenova CS; Fiedler V; Katzer A; Michel K; Deckert S; Zimmermann H; Sukhorukov VL; Flentje M
Oncotarget; 2016 Jun; 7(25):38191-38209. PubMed ID: 27224913
[TBL] [Abstract][Full Text] [Related]
10. Phosphatidylinositol 3-kinases inhibitor LY294002 potentiates the cytotoxic effects of doxorubicin, vincristine, and etoposide in a panel of cancer cell lines.
Badinloo M; Esmaeili-Mahani S
Fundam Clin Pharmacol; 2014 Aug; 28(4):414-22. PubMed ID: 23837575
[TBL] [Abstract][Full Text] [Related]
11. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
Guenther MK; Graab U; Fulda S
Cancer Lett; 2013 Sep; 337(2):200-9. PubMed ID: 23684925
[TBL] [Abstract][Full Text] [Related]
12. Phosphatidylinositol 3-kinase inhibition broadly sensitizes glioblastoma cells to death receptor- and drug-induced apoptosis.
Opel D; Westhoff MA; Bender A; Braun V; Debatin KM; Fulda S
Cancer Res; 2008 Aug; 68(15):6271-80. PubMed ID: 18676851
[TBL] [Abstract][Full Text] [Related]
13. Distinctive regulation and function of PI 3K/Akt and MAPKs in doxorubicin-induced apoptosis of human lung adenocarcinoma cells.
Zhao Y; You H; Yang Y; Wei L; Zhang X; Yao L; Fan D; Yu Q
J Cell Biochem; 2004 Feb; 91(3):621-32. PubMed ID: 14755690
[TBL] [Abstract][Full Text] [Related]
14. CD133 and DNA-PK regulate MDR1 via the PI3K- or Akt-NF-κB pathway in multidrug-resistant glioblastoma cells in vitro.
Xi G; Hayes E; Lewis R; Ichi S; Mania-Farnell B; Shim K; Takao T; Allender E; Mayanil CS; Tomita T
Oncogene; 2016 Jan; 35(2):241-50. PubMed ID: 25823028
[TBL] [Abstract][Full Text] [Related]
15. Effect of ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor, on DNA-dependent protein kinase.
Kong D; Yaguchi S; Yamori T
Biol Pharm Bull; 2009 Feb; 32(2):297-300. PubMed ID: 19182393
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of the PI3 kinase/Akt pathway enhances doxorubicin-induced apoptotic cell death in tumor cells in a p53-dependent manner.
Fujiwara Y; Kawada K; Takano D; Tanimura S; Ozaki K; Kohno M
Biochem Biophys Res Commun; 2006 Feb; 340(2):560-6. PubMed ID: 16378598
[TBL] [Abstract][Full Text] [Related]
17. Class I PI3 kinase inhibition by the pyridinylfuranopyrimidine inhibitor PI-103 enhances tumor radiosensitivity.
Prevo R; Deutsch E; Sampson O; Diplexcito J; Cengel K; Harper J; O'Neill P; McKenna WG; Patel S; Bernhard EJ
Cancer Res; 2008 Jul; 68(14):5915-23. PubMed ID: 18632646
[TBL] [Abstract][Full Text] [Related]
18. Differential effects of the Akt inhibitor MK-2206 on migration and radiation sensitivity of glioblastoma cells.
Djuzenova CS; Fiedler V; Memmel S; Katzer A; Sisario D; Brosch PK; Göhrung A; Frister S; Zimmermann H; Flentje M; Sukhorukov VL
BMC Cancer; 2019 Apr; 19(1):299. PubMed ID: 30943918
[TBL] [Abstract][Full Text] [Related]
19. PI3K inhibitors prime neuroblastoma cells for chemotherapy by shifting the balance towards pro-apoptotic Bcl-2 proteins and enhanced mitochondrial apoptosis.
Bender A; Opel D; Naumann I; Kappler R; Friedman L; von Schweinitz D; Debatin KM; Fulda S
Oncogene; 2011 Jan; 30(4):494-503. PubMed ID: 20856197
[TBL] [Abstract][Full Text] [Related]
20. Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.
Donev IS; Wang W; Yamada T; Li Q; Takeuchi S; Matsumoto K; Yamori T; Nishioka Y; Sone S; Yano S
Clin Cancer Res; 2011 Apr; 17(8):2260-9. PubMed ID: 21220474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
